This move is archived. Current quotes and coverage live on the stock page.
Follow HBP
Helix BioPharma Corp. has seen a significant surge in its stock price, closing up 5.07% in the latest trading session.
Helix BioPharma Corp. (HBP.TO) experienced a notable increase in its stock price, closing at CA$1.45, marking a 5.07% gain. This upward movement comes despite the absence of specific news driving the stock, suggesting underlying investor confidence or market trends at play.
Investor takeaway: Investors should consider the recent upward momentum in Helix BioPharma's stock as a potential indicator of growing market interest, even in the absence of major announcements.
Helix BioPharma Corp.
HBP.TO
HBP.TO
Helix BioPharma Corp.
WealthAwesomeMarket cap
$68.74M
52W high
$2.60
52W low
$0.82
1W change
-11.76%
Beta
-0.14
Analyst Price Targets
Based on analyst covering HBP · as of Sep 17, 2026
Wall Street analysts forecast HBP stock price to rise 177.8% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$2.50
+177.8% Upside
Current Price
C$0.90
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on HBP's historical volatility
30-Day Vol
110.1%
Annualized
90-Day Vol
88.7%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$0.75
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.85 | C$0.58 – C$1.24 |
| 60 trading days | C$0.80 | C$0.47 – C$1.37 |
| 90 trading days | C$0.75 | C$0.39 – C$1.45 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Helix BioPharma Corp. Up 5.07% in One Day
The stock's market cap now stands at approximately CA$110.75 million, indicating a growing valuation amidst a competitive biotech landscape.
Bull case
The recent gain may reflect growing investor confidence in Helix BioPharma's long-term prospects. As the biotech sector continues to attract attention for its potential innovations, investors might see this as a positive sign for the company's future.
Bear case
However, without significant news or financial results to back up the price increase, there's a risk that the stock could experience volatility or corrections soon. Investors should keep this in mind as they assess the stock's performance.
Market Performance Overview
Helix BioPharma's stock closed at CA$1.45, reflecting a 5.07% increase in the latest trading session. This performance stands out in a market where many biotech stocks are experiencing fluctuations, suggesting a potential shift in investor interest.
Investor Sentiment and Future Outlook
Despite the lack of specific news, the rise in Helix BioPharma's stock may indicate growing confidence among investors. As the biotech sector continues to expand, companies like Helix could benefit from increased attention and investment.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
